药品详细
Pipecuronium(哌库)
化学结构式图
中文名
哌库
英文名
Pipecuronium
分子式
C35H62N4O4
化学名
4-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-4-(4,4-dimethylpiperazin-4-ium-1-yl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1,1-dimethylpiperazin-1-ium
分子量
Average: 602.8912
Monoisotopic: 602.477106492
Monoisotopic: 602.477106492
CAS号
68399-58-6
ATC分类
M03A 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.
生产厂家
- Organon usa inc
封装厂家
参考
| Synthesis Reference | Not Available |
| General Reference | Not Available |
剂型
规格
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
药理
| Indication | Used as a muscle relaxant during anesthesia and surgical procedures. |
| Pharmacodynamics | Pipecuronium is a nondepolarizing neuromuscular blocking agent. Neuromuscular blocking agents produce skeletal muscle paralysis by blocking neural transmission at the myoneural junction. The paralysis is selective initially and usually appears in the following muscles consecutively: levator muscles of eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis, and finally, the intercostal muscles and the diaphragm. Neuromuscular blocking agents have no clinically significant effect on consciousness or the pain threshold. |
| Mechanism of action | Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents. |
| Absorption | Not Available |
| Volume of distribution | Not Available |
| Protein binding | Not Available |
| Metabolism |
Not Available
|
| Route of elimination | Not Available |
| Half life | Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB] |
| Clearance | Not Available |
| Toxicity | Not Available |
| Affected organisms |
|
| Pathways | Not Available |
理化性质
| Properties | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | |||||||||||||||||||||||||||||||||||||||
| Experimental Properties | Not Available | |||||||||||||||||||||||||||||||||||||||
| Predicted Properties |
|
|||||||||||||||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Amikacin | The agent increases the effect of muscle relaxant |
| Clindamycin | The agent increases the effect of muscle relaxant |
| Gentamicin | The agent increases the effect of muscle relaxant |
| Lincomycin | The agent increases the effect of muscle relaxant |
| Netilmicin | The agent increases the effect of muscle relaxant |
| Piperacillin | The agent increases the effect of the muscle relaxant |
| Tobramycin | The agent increases the effect of the muscle relaxant |
食物相互作用
Not Available
收藏